RU58841: Is it safe or does it have strange side effects?

What is RU58841, and why is it gaining attention?

RU58841 is a non-steroidal anti-androgen (NSAA) first described in the 1990s and investigated as a possible treatment for androgenic alopecia (male and female pattern hair loss) and acne. Unlike approved medications such as finasteride, which works systemically by inhibiting 5-alpha reductase to reduce dihydrotestosterone (DHT) throughout the body, RU58841 was designed to compete with DHT at the androgen receptor at the site where it is applied.

In animal studies it produced strong local anti-androgen effects. In people, the evidence points away from "blocking DHT at the scalp without affecting the rest of the body". In a small 2026 study, one 30 mg application of an RU58841 product to the scalp of six healthy men left RU58841 and one of its metabolites in their blood, which the authors describe as "considerable systemic exposure" (Okutan et al., 2026). The study did not look at side effects or at repeated or long-term use. Earlier rat work, which gave these compounds into a vein, found that this class forms a shared metabolite with systemic activity; RU58841 formed very little of it and showed no systemic effect in those rats (Cousty-Berlin et al., 1994). The human finding above is the more relevant one.

The prospect of a treatment that targets hair loss without affecting the rest of the body is what draws people to it. The rest of this article looks at what is actually documented — and at how much is not.

Who makes RU58841?: Brands and laboratories producing it

RU58841 is not an approved pharmaceutical product, so it is not manufactured by regulated pharmaceutical companies and no pharmacy dispenses it. What exists instead is material sold by chemical suppliers under a "for research purposes only" label — a designation that keeps the sale outside medicines regulation rather than one that says anything about the product's suitability for people.

We do not name suppliers. The point that matters for safety is the same whichever one is involved: none of them operate under pharmaceutical manufacturing standards, so identity, purity, concentration and stability are not guaranteed, and those variables affect both what a user experiences and what any side effect can be attributed to. A certificate of analysis supplied by a seller is not regulatory oversight of a medicine, and it does not make the product safe to use.

How is RU58841 used? Topical vs. oral application

RU58841 was designed as a topical compound, and the published animal work applied it to the skin. There is no approved dose, concentration, vehicle or frequency for it, because no regulator has approved it for any human use and no human dosing trial has been published. This article does not describe how to prepare or apply it. Some community members mix their own preparations from powder; that is unregulated, the resulting concentration is unverified, and the risk sits with the person doing it.

Oral use is not supported by anything. RU58841 was studied as a localised treatment; swallowing it would be expected to raise systemic exposure substantially, closer to the profile of oral anti-androgens such as bicalutamide, which are prescribed with monitoring in prostate cancer care. There is no research on oral RU58841 for hair loss, and it would carry unknown risks.

Even the topical route lacks long-term safety data in people.

The safety debate: Promising potential or uncharted territory?

The safety question for RU58841 is not really "does it work" — it is what is happening that nobody has measured. Apart from one small absorption study in people, the available evidence is preclinical, so anything said about long-term human safety is inference.

Matias and Gaillard (1995) reported that topically applied RU 58841 inhibited sebaceous gland growth locally in a hamster model — evidence of androgen blockade at the site of application, in an animal, in a tissue that is not a hair follicle. De Brouwer and colleagues (1997) ran a controlled study of RU58841's effect on human balding scalp grafts maintained on testosterone-conditioned nude mice, the closest thing to human tissue data available. Pan and colleagues (1998) reported regrowth in the bald scalp of stumptailed macaques, a species whose skin and hair growth are closer to ours. These studies are small, short, and none of them followed a living person.

Before 2026 the only related work was in rats: Cousty-Berlin and colleagues (1994) gave compounds of this class into a vein and found a common metabolite with systemic activity, but RU58841 formed very little of it. That study did not measure absorption through skin. The 2026 human study then found RU58841 in the blood after a single scalp application (Okutan et al., 2026), so "it stays in the scalp" is not supported. That study used one dose and did not look at side effects, so whether regular use causes systemic effects in people has not been studied.

The rest of what circulates is anecdote from people experimenting on themselves. Forums and online communities carry mixed reports — some describe substantial regrowth, others report fatigue, mental fog, or symptoms they attribute to hormonal change. These reports have no control group and no verified product, so they cannot separate a genuine drug effect from coincidence, from an unrelated cause, or from an impure or wrongly concentrated preparation.

User Experience

Many community members say RU58841 produced visible regrowth for them. Safety is the recurring concern, because there are no long-term clinical studies. One user described severe side effects, including heart palpitations and shortness of breath, and stopped using it entirely. Others raise systemic absorption — the possibility that the compound circulates beyond the scalp. The 2026 human study suggests that concern is justified. Some point out that microneedling or broken skin would be expected to increase how much is absorbed; that has not been tested either.

Home-made preparations come up often. Those who mix their own report inconsistent results and worry about contamination and incorrect concentration. No version, home-made or pre-made, is a regulated medicine or has verified contents.

Side-effect management is also discussed, and some of that discussion is wrong. One recurring suggestion is drinking grapefruit juice to reduce systemic side effects. This is backwards. Grapefruit inhibits the CYP3A4 enzyme, which slows the breakdown of many drugs and therefore raises their levels in the blood. If it had any effect here, it would be expected to increase systemic exposure and side-effect risk, not reduce it. Grapefruit interactions are a documented cause of harm with prescription medicines, and this is not a safety measure. Members also discuss cycling on and off; no evidence supports that either.

Other users report no adverse effects, including after prolonged use. Some describe combining RU58841 with approved treatments such as minoxidil and finasteride, reporting faster regrowth but mixed experiences with side effects — some find the combination helpful, others report increased shedding or scalp irritation. Combining an unapproved compound with prescription medication is something a prescriber should know about.

The community also compares RU58841 to approved treatments. Some members move to RU58841 after sexual side effects on finasteride, describing it as a topical alternative. That comparison is anecdotal: there is no clinical evidence that RU58841 is safer than finasteride, and no human safety data on it at all, so "safer" is not a claim the evidence supports in either direction. Finasteride's reported side effects are also not only sexual: its US label lists depression and suicidal thoughts, breast and semen changes, and sexual dysfunction that some men report continuing after stopping, and the UK regulator (MHRA, May 2026) says depression, suicidal thoughts and sexual dysfunction "may persist after treatment is stopped"; because these are voluntary reports, how often that happens is not known (see the FAQ "Is finasteride safe?").

In summary, community feedback describes RU58841 as promising and risky in roughly equal measure. Those who tolerate it praise the regrowth; others report serious symptoms or inconsistent home-made preparations. The recurring theme is caution, and the reason is that RU58841 is unapproved and has no long-term human safety data.

Potential side effects: Strange surprises or exaggerated fears?

The side effects reported in forums include scalp irritation, shedding (common with many hair-loss treatments as follicles cycle), fatigue and brain fog. All are self-reported, none come from clinical data, and it is not possible to say whether they come from RU58841 itself, from an impure or mis-concentrated preparation, or from something unrelated.

The larger unknown is long-term impact. Because RU58841 acts at the androgen receptor, receptor-level adaptation over time is a theoretical concern, as is interference with androgen-dependent processes elsewhere in the body if enough is absorbed. Both remain open questions; there are no long-term human studies to answer them. Because RU58841 reaches the blood, it could cause effects seen with other anti-androgens, such as breast tenderness or enlargement and sexual side effects. Anti-androgens can affect the development of a male fetus, so anyone who is pregnant or could become pregnant should not use RU58841.

RU58841 remains an experimental compound. It is not available as a medicine, its long-term effects are unknown, there is no established dose, and the one human study found it reaches the blood after a single scalp application. That study, early animal work and user reports are the whole evidence base.

Talk to a doctor or pharmacist before starting, stopping or combining RU58841 or any hair-loss treatment — including if you are already using it, since anyone treating you needs to know what you are applying and what else it might interact with. If you develop chest symptoms, breathlessness, or any sudden change while using it, seek medical attention rather than asking a forum.

References

Battmann, T., Bonfils, A., Branche, C., et al. (1994). RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. Journal of Steroid Biochemistry and Molecular Biology, 48(1), 55-60. https://pubmed.ncbi.nlm.nih.gov/8136306/

Matias, J. R., & Gaillard, M. (1995). Local inhibition of sebaceous gland growth by topically applied RU 58841. Annals of the New York Academy of Sciences, 761, 56-65. https://pubmed.ncbi.nlm.nih.gov/7625751/

De Brouwer, B., Tetelin, C., Leroy, T., et al. (1997). A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice. British Journal of Dermatology, 137(5), 699-702. https://pubmed.ncbi.nlm.nih.gov/9415227/

Pan, H. J., Wilding, G., Uno, H., et al. (1998). Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine, 9(1), 39-43. https://pubmed.ncbi.nlm.nih.gov/9798729/

Cousty-Berlin, D., Bergaud, B., Bruyant, M. C., et al. (1994). Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: relation of their systemic activity to the formation of a common metabolite. Journal of Steroid Biochemistry and Molecular Biology, 51(1-2), 47-55. https://pubmed.ncbi.nlm.nih.gov/7947350/

Okutan, A., Krug, O., Fußhöller, G., Piper, T., & Thevis, M. (2026). Investigation Into the Metabolism and Elimination Behavior of RU 58841, and Its Influence on the Steroid Profile in Humans. Biomedical Chromatography, 40(10), e70602. https://pubmed.ncbi.nlm.nih.gov/42615108/

U.S. Food and Drug Administration. (n.d.). "Drug development and approval process." Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs

Reddit. (2025, January 31). Is anyone using RU58841 against acne? Retrieved from https://reddit.com/r/tressless/comments/1iefsgk/

Reddit. (2024, December 28). Anyone who used RU58841 without fin/dut? Retrieved from https://reddit.com/r/tressless/comments/1hntviz/

Reddit. (2024, December 23). A scary individual report of RU58841. Retrieved from https://reddit.com/r/tressless/comments/1hkieio/